Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Role: lead

NCT07040202Recruiting

Immune Responses to Dengue and Sepsis

Role: lead

NCT04706130Phase 4Completed

Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure

Role: collaborator

NCT04829630Not ApplicableCompleted

Immunity Persistence After Abridged Intradermal Rabies PEP

Role: collaborator

NCT05684185Completed

Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia

Role: lead

All 5 trials loaded